Reported Q: Q3 2025 Rev YoY: +2.7% EPS YoY: +15.0% Move: +1.74%
Prestige Consumer
PBH
$66.49 1.74%
Exchange NYSE Sector Healthcare Industry Medical Distribution
Q3 2025
Published: Feb 6, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for PBH

Reported

Report Date

Feb 6, 2025

Quarter Q3 2025

Revenue

290.32M

YoY: +2.7%

EPS

1.22

YoY: +15.0%

Market Move

+1.74%

Previous quarter: Q2 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $290.32M up 2.7% year-over-year
  • EPS of $1.22 increased by 15% from previous year
  • Gross margin of 55.5%
  • Net income of 61.03M
  • ""We've reduced our variable term loan debt balance to zero and continued to opportunistically repurchase shares, while improving our leverage ratio to 2.5x."" - Ron Lombardi
PBH
Prestige Consumer Healthcare Inc

Executive Summary

In Q3 2025, Prestige Consumer Healthcare Inc reported robust performance, achieving record sales of $290.3 million, a 2.7% increase year-over-year despite industry challenges. The increase reflects the companyÒ€ℒs effective capital allocation strategies and growth in its international markets, particularly the Hydralyte brand. EBITDA margins remained solid in the low 30s, with a notable 15% rise in earnings per share (EPS) to a record $1.22, bolstered by reduced interest expenses and disciplined share repurchases. The management's outlook remains positive, with expectations for a strong finish in Q4, anticipating revenues parallel to Q3, and addressing potential headwinds from global tariff implications.

Key Performance Indicators

Revenue
Increasing
290.32M
QoQ: 2.39% | YoY: 2.68%
Gross Profit
Increasing
161.05M
55.47% margin
QoQ: 2.33% | YoY: 1.97%
Operating Income
Increasing
91.96M
QoQ: 9.04% | YoY: 5.91%
Net Income
Increasing
61.03M
QoQ: 12.24% | YoY: 15.05%
EPS
Increasing
1.23
QoQ: 11.82% | YoY: 14.95%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 249.53 0.95 -6.6% View
Q4 2025 296.76 1.00 +7.1% View
Q3 2025 290.32 1.22 +2.7% View
Q2 2025 283.55 1.09 -1.0% View
Q1 2025 267.14 0.98 -4.4% View